Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycemic control in T1D and T2D

Objectives: The basal insulin analog LY2605541 (LY) is a PEGylated insulin lispro with a large hydrodynamic size which delays insulin absorption and reduces clearance, resulting in prolonged duration of action. Improved glycemic control with insulin generally results in weight gain. The present studies investigated how once-daily LY that showed glycemic control comparable with or superior to insulin glargine (GL), relates to weight gain in patients with type 1 or type 2 diabetes. Methods: Data on body weight were investigated from two studies with LY versus GL. In the first open label, randomized, parallel study…